Successful Neoadjuvant Therapy with Pembrolizumab Monotherapy for Advanced Ascending Colon Cancer
Immune checkpoint inhibitors have emerged as an effective standard of care for deficient mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (CRC). However, the role of immunotherapy in the neoadjuvant setting remains uncertain. We report a patient with advanc...
Saved in:
Main Authors: | Chien-Tzu Huang*, Jeng-Shiun Du |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2023-07-01
|
Series: | Journal of Cancer Research and Practice |
Subjects: | |
Online Access: | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00005 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Durable Clinical Benefit after Dual Checkpoint Inhibition and Single-agent Nivolumab Following Pembrolizumab Failure in Mismatch Repair-deficient Colon Cancer
by: Yat-Fung Chow, et al.
Published: (2023-10-01) -
Effect of RAS mutations and related immune characteristics on the prognosis of patients with MSI-H/dMMR colorectal cancer
by: Yupeng Jiang, et al.
Published: (2025-02-01) -
Clinical Use of Dostarlimab in Advanced Stage and Recurrent Endometrial Cancer: Patient Selection and Perspectives
by: Bujnak AC, et al.
Published: (2025-01-01) -
Identifying factors for pembrolizumab eligibility in head and neck cancer
by: Satoru Miyamaru, et al.
Published: (2025-02-01) -
Frequency and Molecular Characteristics of Mismatch Repair-deficient Status among Multiple Synchronous Colorectal Cancers
by: Kenichi Chikatani, et al.
Published: (2025-01-01)